Clinical trial
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous…
NCT00004744 · National Institute of Neurological Disorders and Stroke (NINDS), NIH · Completed
Key facts
| NCT number | NCT00004744 |
|---|---|
| Title | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis |
| Lead sponsor | National Institute of Neurological Disorders and Stroke (NINDS), NIH |
| Collaborators | Mayo Clinic |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | immune globulin |
| Enrollment | 76 |
| Start date | Feb 1, 1993 |
| Primary completion | Sep 1, 1998 |
| First posted | Feb 25, 2000 |
| Last update posted | Sep 9, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: